OncoMatch/Clinical Trials/NCT07884344
Window of Opportunity Study of Lixumistat in Patients With Newly Diagnosed Glioblastoma
Is NCT07884344 recruiting? Yes, currently enrolling (Oct 2026). This Early Phase 1 trial studies multiple treatments including Lixumistat - Cohort 1 and Lixumistat - Cohort 2 for glioblastoma.
Treatment: Lixumistat - Cohort 1 · Lixumistat - Cohort 2 — The purpose of this study is to determine the effect of Lixumistat in patients with newly diagnosed Glioblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Prior therapy
Cannot have received: any prior treatment for GBM
Received any prior treatment for GBM
Cannot have received: investigational agents for GBM
Patients who are receiving any other investigational agents for GBM treatment
Lab requirements
Blood counts
ANC ≥ 1000 cells/µL; Hemoglobin >8 g/dL (transfusion allowed); Platelets ≥100 × 10^9/L
Kidney function
Creatinine clearance >30 mL/min (Cockcroft-Gault, MDRD, or CKD-EPI)
Liver function
Serum total bilirubin ≤1.5 × ULN (unless Gilbert's or disease involvement); AST/ALT ≤3 × institutional ULN
Patient must have adequate bone marrow function as evidenced by: Absolute neutrophil count (ANC) ≥ 1000 cells/µL; Hemoglobin >8 g/dL (Patients are allowed to be transfused to this level); Platelets ≥100 × 10^9 platelets/L. Patient must have adequate hepatic function as evidenced by: Serum total bilirubin ≤1.5 × upper limit of normal (ULN), unless considered due to Gilbert's disease or disease involvement following approval by the Lead Principal Investigator; AST/ALT ≤3 × institutional ULN. Patient must have adequate renal function as evidenced by: Creatinine clearance >30 mL/min (Cockcroft-Gault, MDRD, or CKD-EPI).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07884344 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages